Facebook Twitter Youtube Vk Rss
Facebook Twitter Youtube Vk Rss
  Trending
24/7 Market News Snapshot 29 Sept 2023 September 29, 2023
SeaStar Medical Receives FDA Breakthrough Device Designation for its Selective Cytopheretic Device for Cardiorenal Syndrome September 29, 2023
Femasys Momentum continues after Two Announcements the Week September 29, 2023
24/7 Market News Snapshot 28 Sept 2023 September 28, 2023
FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors September 28, 2023
Next
Prev

24/7 MN – (NASDAQ: XRTX) XORTX shares are up more than 110% in pre-market trading on positive topline results.

  • Jul 13, 2022 at 6:39 AM

Shares are at $2.55 and climbing on 13,000 plus trades and volume of only 2.3 million previous highs earlier this year saw the stock hit $6.0 on more than 27 million shares of volume.

XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

https://www.globenewswire.com/news-release/2022/07/13/2478849/0/en/XORTX-Announces-Positive-Topline-Results-from-Pharmacokinetics-Bridging-Clinical-Trial.html

RelatedNews

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recent News

Follow Us

Facebook-f Twitter Youtube

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

Search by keyword

© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.